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Abstract
It is generally agreed that the goal of resuscitation is survival with neurological and physiological
status similar to that preceding the cardiac arrest. Previously I have argued that the lack of
improvement in outcome from resuscitation over the past 3 to 4 decades, as compared to the
substantial progress made in treatment of ischemic heart disease, is a consequence of the absence of
randomized clinical trials of new interventions and the use of intermediate endpoints such as return of
spontaneous circulation or admittance to hospital. Proponents of these intermediate endpoints have
argued that those involved in the resuscitation have no control over what care is undertaken in the
hospital and hence hospital mortality only adds noise, at best, thus making survival a less sensitive and
less relevant endpoint for evaluation of resuscitation interventions. Recent reports of improvement
in hospital survival have caused me to consider that their argument may have more validity than I had
supposed. In this note I propose a test that gives weight both to the intermediate endpoint and
survival. The test is responsive to the primary goal of testing survival with limited loss of power
compared to a test based only on the intermediate endpoint. The test is illustrated with several
examples.
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Introduction
It is generally agreed that the goal of resuscitation is survival with neurological and physiological
status similar to that preceding the cardiac arrest [2008 AHA endpoint conference] Previously I have
argued that the lack of improvement in outcome from resuscitation over the past 3 to 4 decades, as
compared to the substantial progress made in treatment of ischemic heart disease, is a consequence of
the absence of randomized clinical trials of new interventions and the use of intermediate endpoints
such as return of spontaneous circulation (ROSC) or admittance to hospital. Proponents of these
intermediate endpoints have argued that those involved in the resuscitation have no control over what
care is undertaken in the hospital and hence hospital mortality only adds noise making survival a less
sensitive and less relevant endpoint for evaluation of resuscitation interventions. Recent reports of
improvement in hospital survival post resuscitation have caused me to consider that their argument
may have more validity than I had supposed. [1, 2] Proponents also point out (figure 1) that sample
sizes can be substantially smaller with the use of intermediate endpoints. The justification for using
such intermediate outcomes as the primary endpoint is the belief that they represent a reasonable
surrogate for survival. That is, believe that conditional upon achieving the intermediate endpoint,
subsequent survival should not depend upon an ongoing effect from the interventions administered
prior to achieving the intermediate endpoint.[3] A second reason for use of an endpoint such as
ROSC is logistic; such information can be obtained directly from the agency involved in the
resuscitation whereas survival requires follow-up with community hospitals which adds cost and
complexity for its acquisition. However it should be noted that, in this context, the survival outcome
does not require lengthy follow-up, a common argument for considering an intermediate endpoint.
Previously I proposed using the bivariate outcome (intermediate, ultimate) e.g. (hospital admittance,
survival) and applying a multivariate test such as Hotelling’s T2.[4] Under the assumption of
surrogacy such an approach also reduces required sample sizes substantially. However, the test is
likely to be significant if there is a large intermediate effect but no net effect and thus this approach
suffers from many of the issues that relate to surrogate endpoints.
The perils of surrogate endpoints are well recognized.[5, 6] Indeed, it can be argued that to establish
an intermediate endpoint as a surrogate for a specific condition and a specific intervention would
require a trial of such size as to make the use of the intermediate unnecessary.[7] Instead, believe in
an intermediate endpoint as a surrogate develops over time as it is found to fit the criteria over a
number of interventions and through basic research that identifies causal pathways.[8-11] In a trial
(TeleCPR) of bystander administered cardio-pulmonary resuscitation (CPR) comparing chest
compression only versus ventilation and chest compression based on instructions administered over
the telephone by EMS dispatchers, admittance to the hospital appeared to be a reasonable surrogate for
survival.[12] However, at least two trials of interventions in resuscitation question the validity of
hospital admittance as a surrogate for survival (ARREST, a trial of amiodarone (an antiarrhythmia
drug) administered at the scene, which found increased hospital admittance but no effect on survival;
and ASPIRE, a trial of mechanical CPR, which found no effect on hospital admittance but decreased
survival).[13, 14] Absence of surrogacy could be that survival, conditional on reaching the positive
intermediate outcome, was either reduced or increased for the intervention compared to control. I will
refer to these as sub- (reverse- if all apparent gain from the intermediate is lost) and super-surrogate
conditions, as compared with surrogacy in which the effect of the intervention is directionally similar
and proportionately comparable between the intermediate endpoint and final outcome.
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A desirable test would reject the intervention if survival was reduced, would optimally weight both the
intermediate and survival if there was evidence of super-surrogacy, would rely on the intermediate if
there was no evidence against surrogacy, and would give relatively more weight to survival if there
was evidence of sub or reverse-surrogacy. In this note I propose such a test, investigate its properties
through simulation, and discuss what such a test might have meant for the TeleCPR, ARREST and
ASPIRE trials and for a potential trial of mild hypothermia (mild hypothermia initiated at the scene of
the arrest is an intervention that might be supposed to be a super-surrogate in that cooling might help
achieve ROSC (if given prior to it) and might improve survival conditional on ROSC through its
impact on the brain and other vital organs. [2, 15])
The Proposed Test W
Notation
Let I represent the intermediate endpoint and S the ultimate endpoint of survival. Let intervention, T,
and control, C, represent the therapies to be compared. Suppose 2N patients are to be randomized, N
to treatment and N to control. Let PC and PT = PC + ∆ be the anticipated rates for I under control C
and treatment T. Similar let QC and QT = QC + δ be the anticipated conditional survival, S|I, rates.
Let pT , pC , qT , q C be the corresponding values for the observed data. Let Z (Z S , Z i , Z S | I ) be the
normal approximations for the tests comparing proportions.
When Survival is Reduced ( Z S < 0 )
If Z S < 0 (i.e. evidence of harm) set W to Z S or arbitrarily low, say W = 0 .
When there is Potential Super-surrogacy ( Z S ≥ 0 and Z S | I > 0 )
If Z S ≥ 0 (i.e. no evidence of worsened survival) and Z S | I > 0 (i.e. potential of super-surrogacy) set

sign( Z I ) Z I + Z S |I
2

W=

Z I + Z S |I
2

2

2

.

This is an approximately optimal test of the combined outcomes

(appendix 1).
When there is Evidence of Sub or Reverse Surrogacy ( Z S ≥ 0 and Z S |I < C L < 0 )
If Z S ≥ 0 and Z S | I < C L = 0.6 Eˆ RS where C L is negative (evidence of sub or reverse-surrogacy) define
W = Z I + 3Z S | I which gives 3 times as much weight to survival as to the intermediate.

Here

− QC ∆ / PT

N is the expected value of Z S | I under δ = −QC ∆ / PT which
σ S |I
corresponds to the null for S (i.e. reverse-surrogacy). The choice of the factor 0.6 and the relative
weight of 3 was based on simulations with the object of protecting against accepting the intervention
when survival was actually worsened while maintaining the power of the intermediate outcome.
E RS = E ( Z S | I | δ = −QC ∆ / PT ) =
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When there is no Evidence of Ultimate Harm and little or no Evidence against Surrogacy
( Z S ≥ 0 and 0 ≥ Z S | I ≥ C L )
If Z S ≥ 0 and 0 ≥ Z S | I ≥ C L define W = Z I thus taking advantage of the greater power of the
intermediate endpoint when surrogacy is likely.
Properties of W
Under the compound null and across a wide range of control rates, 0.1 ≤ PC ≤ 0.9 and 0.1 ≤ QC ≤ 0.9 , the
95%tile of W is given by (appendix 2),
W.95 = 1.956 + 0.09672QC − 0.05067 PC

and the 97.5%tile is given by
W.975 = 2.273 + 0.07608QC − 0.037 PC

Indeed for .8 < x < .98, to a very good approximation
W x = qnorm(x) + (-2.213) + 5.2 * x + (-2.676 * x * *2) + (-(.4245 - .3949 * x) * PC ) + (.8346 - .7791 * x) * QC .

The power (appendix 3) of W , Z I and Z S for a 1 sided .05 level test is displayed in Table 1 for some
typical intermediate and conditional control outcome rates: (PC ,QC)= (0.3,0.48), (0.4,0.36) and
(0.6,0.24), all yielding the same control survival rate of 0.144, under alternatives for the intermediate
of PT = PC and 1.4PC (respectively null and substantially better intermediate outcome under treatment
T than control C); and alternatives for the conditional outcome of QT = 1.2 QC , QC , PC QC / PT , and
0.8 PC QC / PT (respectively super-surrogacy, surrogacy, reverse-surrogacy, and moderately worsened
survival). The sample sizes were choosen to correspond to a power of 0.9 for W under the
substantially better intermediate outcome (PT = 1.4PC) and surrogacy (QT = QC).

When the null holds for the intermediate outcome, W and Z S perform similarly (rows 1, 2, and 3).
When there is a substantial effect on the intermediate outcome, there are clear differences between the
tests. Consider the values in italics which correspond roughly to current control rates for ROSC and
survival conditional on ROSC. Under super-surrogacy, W and Z I have the same power, .97, 10%
higher than Z S . Under surrogacy Z I has a power of .97 compared to .90 for W and .53 for Z S . Under
the null for survival W has a power of .38. Under worsened survival W will exceed the critical value
10% of the time. The corresponding N’s required to have a power of .9 for Z I and Z S are 170 and
725 respectively.
Results are similar across a wide range of control rates. For
0.3 ≤ PC ≤ 0.6 , 0.2 ≤ QC ≤ 0.6 , and PC ≤ PT ≤ (1 + PC ) / 2 ,
sample sizes for 80% and 90% power for W , assuming surrogacy, are approximated by
N .8 ≈ exp(.7799 − (1.994 log( PT − PC ) + .179 log(QC ) + .2421 log(1 − QC )))

and
N .9 ≈ exp(.7042 + .2159 log( PT ) − (1.94 log( PT − PC ) + 1.179 log(QC ) + .6551 log(1 − QC ))) .
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Dependence of the intermediate outcome and survival conditional on the intermediate outcome
The above results assumed independence of the intermediate outcome and survival conditional on the
intermediate outcome. Since the dependency structure will generally be unknown, the critical values
for W must be determined under an independence model. However even a strong dependence
(obtained by requiring a given case to have probabilities for each outcome with the same %tile in the
respective distributions, i.e. those more likely to achieve the intermediate outcome are more likely to
survive if the intermediate outcome is achieved and conversely those less likely to achieve the
intermediate outcome are less likely to survive even if the intermediate outcome is achieved) had
negligible impact on the test size (i.e. on the alpha level of the test). Indeed under this strong but
reasonable dependence, the size of W is negligibly smaller than that of Z S (based on 4000 simulations
with N = 1000 and over 0.1 ≤ PC ≤ 0.9 and 0.1 ≤ QC ≤ 0.9 -appendix 4).
Discussion
0

 sign( Z ) Z 2 + Z 2
I
I
S |I

2
2
W =
Z I + Z S |I

ZI

Z I + 3Z S | I


if

ZS < 0

if

Z S ≥ 0 & Z S |I > 0

if
if

Z S ≥ 0 & C L ≤ Z S |I ≤ 0
Z S ≥ 0 & Z S |I < C L

.

W attempts to capture the added efficiency when there is evidence for super-surrogacy, the usual
efficiency of the intermediate outcome when there is evidence for surrogacy and attempts to avoid
type I error when survival is actually worsened by giving substantial weight to the conditional survival
comparison when there is evidence of substantial sub-surrogacy. Even the extreme (though
directionally likely) violation of the assumption of independence of the intermediate and conditional
survival outcomes has little effect on the size of W. W maintains power under super-surrogacy, has
modest losses in power under surrogacy, and substantial protection against claiming an advantage
when survival is worse. There were only modest effects on W when the constant 3 was varied
between 2.5 and 3.5. Varying the constant 0.6 in the value for CL essentially traded power under
surrogacy for protection against surrogacy failure.
Note that W is essentially a one-sided test, which is appropriate for trials comparing a new therapy to a
standard of care.
The TeleCPR Study
The TeleCPR study evaluated the effect on survival of bystander CPR administered according to
instructions from the EMS dispatcher.[12] The randomly assigned instructions either included steps
for ventilation and chest compression (ABC-CPR), the standard of care, or steps for chest compression
only (CC-CPR). The trial was designed as 1-sided, testing whether CC-CPR was superior to ABCCPR as a previous 1-sided trial had demonstrated that CC-CPR was not inferior to ABC-CPR. The
trial terminated with slightly over 500 of a planned 700 patients enrolled when funding ran out. The
data is shown in table 2a. Although there is a slightly greater survival rate conditional on admittance
to the hospital for the CC-CPR arm (36.1% versus 30.5%), this was not significant (one-sided p =
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0.25) so surrogacy could not be rejected. The one-sided p-values for T2, W , Z I and Z S are 0.12,
0.088, 0.084, and 0.097 respectively. One of the problems with the bivariate outcome is defining a
good and a bad outcome. However, in[4] we show, based on economic considerations, that
essentially half of the alpha will result in declaring a good outcome under the null. Because of the
slight super-surrogacy, W is almost as powerful as Z I and Z S loses relatively little power.
The ASPIRE Study
The ASPIRE study was intended to compare manual CPR (the standard of care) with mechanical CPR
provided by a load distributing band device (the AutoPulse).[13] To avoid the idiosyncrasies of
criteria for hospital admission in difference cities, the study considered the endpoint of alive a 4 hours
post the time of call reporting an out-of-hospital cardiac arrest. Investigators estimated that control
rates for this outcome would be 0.178 and anticipated a 35% relative improvement to 0.24 under the
intervention. The estimated rate of survival conditional on being alive at 4 hours was about .4. It
was unclear whether any additional increment should be expected for survival conditional on being
alive at 4 hours in the intervention arm. The sponsor (a startup company funded by venture capital)
and the investigators wanted to do a survival trial, although it was felt that a neutral impact on survival
would be a positive result as the device might substantially reduce manpower requirements. Ignoring
issues such as sequential monitoring, the sample size required (2alpha = 0.05, power = 0.9) for the
intermediate endpoint was 2N ~ 1804 and for survival, assuming surrogacy, was 2N ~ 5320. It was
consider impossible to raise enough money to do a survival study. The sample size that would have
been required for W and T2 would have been 2N ~ 2224 and 2150 respectively. The study was
terminated early due to concerns about safety. The data is shown in Table 2b. The slight trend
toward an improvement in 4 hour survival was not significant. The one-sided p-values for T2, Z I
and Z S are 0.01, 0.32, and 0.024 [note the reduction in survival (the secondary endpoint) was
significant at p = 0.03 after adjustment for baseline covariates]. The point estimates for the
significant bivariate and survival outcomes are indicative of harm. The results of the study are being
largely ignored by the manufacturer on several grounds including that survival was not the primary
endpoint and the difference was not significant (p = 0.06 when considered as a two-sided test) .
Whether or not the sponsor could/would have raised the capitol to finance the study if the outcome
was tested with W is unclear. The study would undoubtedly have been terminated in the same time
frame and the value of W would have been 0 as Z S < 0.

The ARREST Study
The ARREST study evaluated the use of amiodarone in patients with out-of-hospital cardiac arrest
who had not been resuscitated after 3 or more precordial shocks.[14]
This single center study used
hospital admittance as the primary outcome measure with survival as a secondary outcome. This
choice was again made on the practical grounds of financing and feasibility of conducting the study.
Assuming a control rate for hospital admission of 0.41 and a 30% relative improvement with use of
amiodarone, and assuming a survival rate conditional on admittance of approximately .38 and
surrogacy, the sample sizes needed for a 2alpha = 0.05 and power = 0.8 design using T2, W , Z I and
Z S would be 2N = 630, 680, 500, and 2090 respectively. The data are shown in Table 2c. The
improvement in admittance rates was significant (one-sided p = 0.019). Survival was not worse (one-
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sided p = 0.52). It is likely the site might have elected to set the sample size at 680 if they were
convinced that the test W were a valid means of investigating survival. The site chose not to
implement amiodarone as part of standard protocol even though the trial, as designed, had a
significantly positive outcome. However, many other EMS systems did include amiodarone in their
resuscitation protocols. For the data collected, CL = -1.027, ZS|I = -1.133, W.975 = 2.284, and W = 1.234. In this case W would have provided protection against a positive result for an intermediate
endpoint where there was evidence of reverse-surrogacy. The one-sided p-value for T2 was 0.025,
providing an example of how the bivariate outcome can suffer the same problems as the intermediate.

A proposed trial of Mild Hypothermia
A novel means of cooling through the nose has been demonstrated, in animal studies, to produce a
large increase in ROSC long before any real cooling of the brain or vital organs could occur, [16] but
also provides rapid core body cooling suggesting the possibility of additional improvement in hospital
survival as demonstrated in several trials. [2, 15] The control rates based on current outcomes at a
number of sites planning to participate in a randomized trial of this novel approach and anticipated
relative improvements are shown in table 3.

Simulation results for Z I , Z S , and W are shown in Table 4 based on sample sizes which yield a power
for Z I , Z S and W of 0.9 for a 1 sided 0.05 level. If the trial were sized for W and the super-surrogacy
assumption holds W would preserve most of the power of the intermediate, but would relinquish
about 7 % power compared to the intermediate. However, under a modest negative effect on survival
W would indicate a significant positive effect 26% of the time. At first glance this appears to be
unacceptable, but is surely better than using Z I which would have indicated a positive effect 98% of
the time Also recall that for W to be significantly positive Z S has to be positive and thus the data
from the trial would not indicate any worsening of survival. This is similar to the ARREST situation,
except that the effect of mild hypothermia on the intermediate outcome would have been much greater
and would probably result in adoption of the therapy by many EMS agencies. Had the trial been
sized for Z S (2N = 1900) but tested with W this undesirable result would have occurred 14% of the
time, while the power under surrogacy would be almost 100%. Under the surrogacy assumption, the
sample size for the bivariate outcome would be 2N = 526.

Would the use of W change the current assessment of the outcomes of clinical trials in EMS?
Ignoring regulatory/approval concerns, the EMS community, being a group of clinician/scientists,
would consider all evidence including both the intermediate and the survival outcomes when
evaluating the results of a trial, whether the trial was sized for and tested with T2, Z I , Z S or W .
What might the collective judgment be in the case of concern where the unknown truth is that the
intervention has a large positive effect on the intermediate outcome but a modest negative effect on
survival and W yielded a significant p-value? Figure 2 shows the distribution of Z I and Z S for such a
situation (defined by the 4th row of Table 4). In all cases a large effect on the intermediate and a
trend (often substantial) toward a positive effect on survival would be seen. I suspect the EMS
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community would be inclined to adopt the intervention whether the trial was based on Z S or W .
based on Z S adoption would usually be without the “stamp of approval, i.e., p < 0.05”.

If

There are ethical and practical arguments for and against using W in a clinical trial. Some would
argue that only survival matters and only ZS should be used. Others would argue that if there is no net
effect on survival then improvement in the ROSC rate is good because more patients may survive with
improving hospital care. Still others would argue that if there is no net effect on survival then
improvement in the ROSC rate is bad because it results in consumption of unnecessary and expensive
health resources. Others would argue that too large of sample sizes would have a negative effect on
efforts to find and test potentially beneficial interventions. Even if therapies are developed and
suggest potential in phase II trials using an intermediate endpoint, survival trials would probably have
to be funded by NIH. Current funding for the Resuscitation Outcomes Consortium
(http://www.nih.gov/news/pr/mar2006/nhlbiv1-24.htm) constitutes only a small fraction of what
would be needed to conduct all the needed trials. Although each scenario would need to be evaluated,
in my opinion the proposed test, W, is a compromise that may provide for robust and cost-effective
evaluation.
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Table 1
I

Null

Substantial
effect

Power o f Z I , Z S and W for a 1 sided .05 level test
S|I
PC ,QC = 0.3,0.48
PC ,QC = 0.4,0.36
Super-surrogacy
Surrogacy (Null for S|I)
Worsened survival
Super-surrogacy
Surrogacy (Null for S|I)
Reverse surrogacy (Null survival)
Worsened survival

ZI
0.051
0.051
0.051
0.955
0.953
0.954

N=348
ZS
0.272
0.051
0.003
0.953
0.648
0.050

W
0.281
0.051
0.013
0.967
0.901
0.352

0.953

0.003

0.062

PC ,QC = 0.6,0.24

ZI
0.051
0.052
0.052
0.973
0.975
0.974

N=250
ZS
0.226
0.052
0.005
0.873
0.531
0.050

W
0.197
0.052
0.014
0.972
0.900
0.376

ZI
0.048
0.048
0.050
1.000
1.000
1.000

N=203
ZS
0.199
0.050
0.006
0.810
0.460
0.050

W
0.157
0.050
0.014
0.988
0.900
0.414

0.975

0.005

0.100

1.000

0.006

0.152
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Table 2
Table 2a
ABC-CPR
CC-CPR

N
278
240

Results of the TeleCPR Trial
Admitted to Hosp Survived|Admitted
95 (34.2%)
29 (30.1%)
97 (40.4%)
35 (36.1%)

Survived
29 (10.4%)
35 (14.6%)

N
373
394

Results of the ASPIRE Trial
Alive at 4 hours
Survived|Alive4hrs
92 (24.7%)
37 (40.2%)
104 (26.4%)
23 (22.1%)

Survived
37 (9.9%)
23 (5.8%)

N
258
246

Results of the ARREST Trial
Admitted
Survived|Admitted
89 (34.5%)
34 (38.2%)
108(43.9%)
33 (30.6%)

Survived
34(13.2%)
33 (13.4%)

Table 2b
Manual CPR
AutoPulse
Table 2c
Control
Amiodarone
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Table 3
Expected control and intervention rates for the intermediate outcome (ROSC) and survival
conditional on ROSC in a trial of mild hypothermia treatment for Out-of-Hospital Cardiac Arrest.
Control
Expected Rates Under Assumed
Rates
Intervention
Improvement
I (ROSC)
S|I (Survival conditional on ROSC)

40%
36%

54%
41.4%

14%
5.4%
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Table 4
Power of Z I , Z S and W for a 1 sided .05 level test with PC ,QC = 0.4,0.36
I

∆ =.14
Large
Effect
on I

S|I

δ
δ
δ
δ

= .054
=0
= -.0933
= -.1102

Super-surrogacy
Surrogacy (Null for S|I)
Reverse surrogacy (Null for S)
Worsened survival

ZI
0.900
0.901
0.902
0.899

2N=422
ZS
0.684
0.397
0.050
0.028

W
0.873
0.774
0.370
0.281

ZI
1.000
1.000
1.000
1.000

2N=1900
ZS
0.998
0.902
0.051
0.013

W
1.000
0.994
0.308
0.141

ZI
0.976
0.975
0.977
0.977

2N=650
ZS
0.838
0.529
0.050
0.023

W
0.966
0.898
0.377
0.258
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Figure 1

Endpoints and Sample Size in the Setting of Out-ofHospital Cardiac Arrest
(25% improvement in outcome)
Sample size 2 N ~ 4 (Z α / 2 + Z β )2

ROSC

p ~ .6

Admit to ED

2 p (1 − p ) 4 * 9 * 2 1 − p
1− p
~
= 1152
2
2
. 25
p
p
(λ p )
2α = .05

2N ~ 768
p ~ .4

Admit to hospital

β = .1

2N ~ 1728

p ~ .3

Discharge alive from hospital

λ = . 25 (25 % ↑ )

2N ~ 2688
p ~ .07

2N ~ 15305

Discharge alive from hospital neurologically intact

p ~ .05

2N ~ 21888
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Figure 2

Values of ZI by ZS when there is a large positive effect on the intermediate
outcome, a modest negative effect on survival, and W is significant.

ZS

ZI
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Appendix 1

An approximately optimal statistic when Z S ≥ 0 (i.e. no evidence of worsened survival) and Z S | I > 0
(i.e. potential of super-surrogacy).
~
Under the null of no treatment effect on I, Z I = N ( pT − pC ) / σ I ~ N (0 , 1) with σ I2 = 2 P P where
~
P = ( PT + PC ) / 2 and P = 1 − P . Similarly under the null of no treatment effect conditional on I,

1 
~ 1
~ P
 = 2Q Q
Z S |I = N (qT − qC ) / σ S |I ~ N (0 , 1) where σ S2|I = Q Q
. Thus under the
+
PT PC
 PT PC 
composite null, Z = Z (a, b) = aZ I + bZ S | I ~ N (0 , 1) provided a 2 + b 2 = 1 . Under the alternatives,
~
~
PT = PC + ∆ and QT = QC + δ , Z I ~ N ( N ∆ / σ I , 1) where σ I ~ PT PT + PC PC and
~
~
QT QT QC QC
2
Z S |I ~ N N δ / σ S | I , 1 where σ S |I ~
+
so, if the conditional outcome is independent of
PT
PC

(

)

(

)

the intermediate outcome, Z ~ N (a∆ / σ S + bδ / σ U |S ) N , 1 . The null is rejected in favor of the

(

)

alternative if Z > Z 1−α / 2 so the power is Φ(− Z β ) = Φ (a∆ / σ I + bδ / σ S | I ) N − Z 1−α / 2 . This is
maximized when Z S | I > 0 with the ratio a =
b

a ∆ˆ / σˆ I
=
=
b δˆ / σˆ S | I

∆ /σ I
. Estimating from the data,
δ / σ S |I

Z
N ∆ˆ / σˆ I
= I and substituting would give an approximately optimal
N δˆ / σˆ S | I Z S | I

Z I + Z S |I
2

statistic Z = aZ I + bZ S | I ≈

2

Z I + Z S|I
2

2

. Thus if Z S ≥ 0 (i.e. no evidence of worsened survival) and

Z S | I > 0 (i.e. potential of super-surrogacy) an approximately optimal statistic is given by

sign( Z I ) Z I + Z S |I
2

W=

Z I + Z S |I
2

2

2

.
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Appendix 2
S-plus program for the value for W, WC, corresponding to the Cth %tile across
A wide range of intermediate (.1-.9) and conditional (.1-.9) outcome rates
nsim_100000
N_1000
C_.95
wc_vector(length=0)
for (Pc in .1*(1:9)){
Pc_Pc
for (Qc in .1*(1:9)){
Qt_Qc
x1_rbinom(nsim,N,Pc)
x2_rbinom(nsim,N,Pc)
mx2_x2/N
mx1_x1/N
rx_(x1+x2)/(2*N)
sigx_(rx*(1-rx)/N)**.5
y1_rbinom(nsim,x1,Qc)
y2_rbinom(nsim,x2,Qt)
my2_y2/x2
my1_y1/x1
ry_(y1+y2)/(x1+x2)
sigy_(ry*(1-ry)*2/(x1+x2))**.5
u_y1-y2
x_((x1/N)-(x2/N))/(2**.5*sigx)
y_((y1/x1)-(y2/x2))/(2**.5*sigy)
delnull_mx2*my2/(mx1)-my2#estimates the conditional survival delta corresponding to null
#survival effect
EZrs_delnull*(((mx1+mx2)/2)*N)**.5/(((my1+my2)/2)*(1-((my1+my2)/2)))**.5
CL_.6*EZrs
w_(u>=0)*((y>=0)*(sign(x)*x**2+y**2)/((x**2+y**2+.00001)**.5)+(y<0)*(y>=CL)*x+
(y<CL)*(x+3*y))+(u<0)*0#computes W
hist(w,nclass=200)
wo_w[order(w)]
wc_rbind(wc,c(Pc,Qc,wo[C*nsim]))
}}
wcregression_lm(wc[,3]~wc[,1]+wc[,2])
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Appendix 3
S-plus program for comparing power of Zi, Zs, and W for specific control rates and
alternatives for the intermediate of null and substantial improvement and alternatives for
the conditional survival corresponding to super-surrogacy, surrogacy, reverse-surrogacy and
worsened survival
nsim_100000
N_250 #number per group
Pc_.4 #Control rate for intermediate outcome
Qc_.36 #Control rate for conditional survival
power_vector(length=0)
for (Pt in c(Pc,1.4*Pc)){#null and substantial improvement for intermediate outcome
for (Qt in c(Qc*1.2,Qc,Pc*Qc/Pt,.8*Pc*Qc/Pt)){#super-surrogacy, surrogacy, reversesurrogacy, #worsened survival
x1_rbinom(nsim,N,Pt)
x2_rbinom(nsim,N,Pc)
mx2_x2/N
mx1_x1/N
rx_(x1+x2)/(2*N)
sigx_(rx*(1-rx)/N)**.5
y1_rbinom(nsim,x1,Qt)
y2_rbinom(nsim,x2,Qc)
my2_y2/x2
my1_y1/x1
ry_(y1+y2)/(x1+x2)
sigy_(ry*(1-ry)*2/(x1+x2))**.5
ru_(y1+y2)/(2*N)
u_((y1-y2)/N)/(ru*(1-ru)*2/N)**.5
x_((x1/N)-(x2/N))/(2**.5*sigx)
y_((y1/x1)-(y2/x2))/(2**.5*sigy)
w95_1.956 + (-0.05067*Pc) + (.09672*Qc)#critical value for W-see appendix 1
delnull_mx2*my2/(mx1)-my2#estimates the conditional survival delta corresponding to null
#survival effect
EZrs_delnull*(((mx1+mx2)/2)*N)**.5/(((my1+my2)/2)*(1-((my1+my2)/2)))**.5
CL_.6*EZrs
w_(u>=0)*((y>=0)*(sign(x)*x**2+y**2)/((x**2+y**2+.00001)**.5)+(y<0)*(y>=CL)*x+
(y<CL)*(x+3*y))+(u<0)*0#computes W
pw_sum(w>=w95)/nsim
px_sum(x>=1.64)/nsim
pu_sum(u>=1.64)/nsim
power_rbind(power,c(px,pu,pw))
}}
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Appendix 4
S-plus program for creating dependent outcome data and evaluating size
#converting mean, m, and stdev, s, into alpha and beta parameter
#for beta dist (NOTE s**2<m-m**2)!!!!!!!
betapara_function(m,s)
{if (s**2>=m-m**2) return("warning")
if(s**2<m-m**2)
{b_(((m/s)**2)*(1-m)**2/m)-(1-m)
a_(m/(1-m))*b
return(c(a,b))}}
getdata_function(nsims,Pc,Pt,Qc,Qt,N){
#for control
pab_betapara(Pc,.05)#returns the parameters of a beta dist with mean Pc and stdev .05
pc_rbeta(nsims*N,pab[1],pab[2])#generates individual probabilities for intermediate outcome
qab_betapara(Qc,.05)
qc_qbeta(pbeta(pc,pab[1],pab[2]),qab[1],qab[2])#generates individual probabilities for
#survival conditional on intermediate outcome with same %tile as the individuals %tile
#for probability of the intermediate outcome
xc_rbinom(nsims*N,1,pc)#generates the intermediate outcome
qc_qc*xc#sets the conditional survival probability to zero if the intermediate outcome is
not #reached
yc_rbinom(nsims*N,1,qc)#generates the survival outcome
#for intervention
pab_betapara(Pt,.05)
pt_rbeta(nsims*N,pab[1],pab[2])
qab_betapara(Qt,.05)
qt_qbeta(pbeta(pt,pab[1],pab[2]),qab[1],qab[2])
xt_rbinom(nsims*N,1,pt)
qt_qt*xt
yt_rbinom(nsims*N,1,qt)
return(rbind(xc,yc,xt,yt))}
#driver
nsim_100
N_1000
k_40#total number of simulations is k*nsim
out_vector(length=0)
for (i in 1:k){
power_vector(length=0)
for (Pc in .1*(1:9)){
for (Qc in .1*(1:9)){
data_getdata(nsim,Pc,Pc,Qc,Qc,N)
xc_data[1,]
xt_data[3,]
yc_data[2,]
yt_data[4,]
xc_matrix(xc,N,nsim)
xt_matrix(xt,N,nsim)
yc_matrix(yc,N,nsim)
yt_matrix(yt,N,nsim)
x1_colSums(xc)
x2_colSums(xt)
y1_colSums(yc)
y2_colSums(yt)
mx2_x2/N
mx1_x1/N
rx_(x1+x2)/(2*N)
sigx_(rx*(1-rx)/N)**.5
my2_y2/x2
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my1_y1/x1
ry_(y1+y2)/(x1+x2)
sigy_(ry*(1-ry)*2/(x1+x2))**.5
ru_(y1+y2)/(2*N)
u_((y1-y2)/N)/(ru*(1-ru)*2/N)**.5#computes Zs
x_((x1/N)-(x2/N))/(2**.5*sigx)#computes Zi
y_((y1/x1)-(y2/x2))/(2**.5*sigy)#computes Zs|i
w95_1.956 + (-0.05067*Pc) + (.09672*Qc)#critical value for W-see appendix 1
delnull_mx2*my2/(mx1)-my2#estimates the conditional survival delta corresponding to null
#survival effect
EZrs_delnull*(((mx1+mx2)/2)*N)**.5/(((my1+my2)/2)*(1-((my1+my2)/2)))**.5
CL_.6*EZrs
w_(u>=0)*((y>=0)*(sign(x)*x**2+y**2)/((x**2+y**2+.00001)**.5)+(y<0)*(y>=CL)*x+
(y<CL)*(x+3*y))+(u<0)*0#computes W
pw_sum(w>=w95)/nsim
px_sum(x>=1.64)/nsim
pu_sum(u>=1.64)/nsim
power_rbind(power,c(Pc,Qc,px,pu,pw))
}}
out_cbind(out,power)}
#averages across the k runs and reassembles matrix
pq_out[,1:2]
pw_out[,5*(1:k)-0]
pu_out[,5*(1:k)-1]
px_out[,5*(1:k)-2]
pwa_rowMeans(pw)
pua_rowMeans(pu)
pxa_rowMeans(px)
size_cbind(pq,pxa,pua,pwa)
wusize_lm(size[,5]-size[,4]~size[,1]+size[,2])
wusize
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